



## Drug Delivery to Brain Tumours

Guest Editor:

**Dr. Sarah Shigdar**

1. School of Medicine, Deakin University, Geelong, VIC 3128, Australia

2. Centre for Molecular and Medical Research, Deakin University, Geelong, VIC 3128, Australia

Deadline for manuscript submissions:

**closed (25 March 2022)**

### Message from the Guest Editor

A key challenge in the treatment of brain tumours, either primary or secondary, is drug delivery to the brain. This is due to the unique anatomical structure and a distinctive microenvironment, cell types, and metabolism of the brain and the blood–brain barrier (BBB). Despite rigorous scientific attempts to improve the treatment of these patients, current treatments, and invasive surgeries, radiotherapies, or chemotherapies, patients have a low survival rate and a poor quality of life. The aim of this Special Issue is to gather the latest discoveries in drug delivery to brain tumours. This includes improvements in understanding the biology of the brain and brain tumours, and novel methodologies in delivering drugs to these tumours. These methods include but are not limited to novel formulations of current therapeutics, application of aptamers, nanomedicines (lipid-based, polymer-based, or carbon based), biological vectors, invasive methods, and methods affecting the integrity of BBB. This Special Issue is open to cutting-edge research papers, case reports, and review papers.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)